Atlas of Butterflies and Diurnal Moths in the Monsoon Tropics of Northern Australia

"Northern Australia is one of few tropical places left on Earth in which biodiversity—and the ecological processes underpinning that biodiversity—is still relatively intact. However, scientific knowledge of that biodiversity is still in its infancy and the region remains a frontier for biological discovery. The butterfly and diurnal moth assemblages of the area, and their intimate associations with vascular plants (and sometimes ants), exemplify these points. However, the opportunity to fill knowledge gaps is quickly closing: proposals for substantial development and exploitation of Australia’s north will inevitably repeat the ecological devastation that has occurred in temperate southern Australia—loss of species, loss of ecological communities, fragmentation of populations, disruption of healthy ecosystem function and so on—all of which will diminish the value of the natural heritage of the region before it is fully understood and appreciated. Written by several experts in the field, the main purpose of this atlas is to compile a comprehensive inventory of the butterflies and diurnal moths of northern Australia to form the scientific baseline against which the extent and direction of change can be assessed in the future. Such information will also assist in identifying the region’s biological assets, to inform policy and management agencies and to set priorities for biodiversity conservation.

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

New locations of butterflies from northern Arnhem Land, Northern Territory

Volume: 24Start Page: 2End Page: 1

Jarrad Holmes, Deborah Bisa, Audrey Hill, Beth Crase

Made available by the Northern Territory Library via the Publications (Legal Deposit) Act 2004 (NT).Introduction -- 1. The Litchfield Shire -- 2. Identifying plants using this book -- 3. Plant descriptions -- 4. Management issues within the Litchfield Shire -- 4.1 Land clearing for horticulture, rural and urban development -- 4.2 Mining -- 4.3 Introduction of weeds and feral animals 4.4 Changing fire regimes -- 4.5 Changing groundwater resources -- 5. Community involvement -- 6. How conservation status is assigned to a species -- 7. Collecting and preserving plant specimens -- Glossary -- Habitat photos -- Botanical terms -- Illustrations of botanical terms -- References.Logos on cover: Threatened Species Network ; WWF ; Natural Heritage Trust ; Top End Native Plant Society. Includes bibliographical references and index

Atlas of Butterflies and Diurnal Moths in the Monsoon Tropics of Northern Australia

"Northern Australia is one of few tropical places left on Earth in which biodiversity—and the ecological processes underpinning that biodiversity—is still relatively intact. However, scientific knowledge of that biodiversity is still in its infancy and the region remains a frontier for biological discovery. The butterfly and diurnal moth assemblages of the area, and their intimate associations with vascular plants (and sometimes ants), exemplify these points. However, the opportunity to fill knowledge gaps is quickly closing: proposals for substantial development and exploitation of Australia’s north will inevitably repeat the ecological devastation that has occurred in temperate southern Australia—loss of species, loss of ecological communities, fragmentation of populations, disruption of healthy ecosystem function and so on—all of which will diminish the value of the natural heritage of the region before it is fully understood and appreciated. Written by several experts in the field, the main purpose of this atlas is to compile a comprehensive inventory of the butterflies and diurnal moths of northern Australia to form the scientific baseline against which the extent and direction of change can be assessed in the future. Such information will also assist in identifying the region’s biological assets, to inform policy and management agencies and to set priorities for biodiversity conservation.